Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

What was studied

This study looked at how experts judged who had CIDP before the ADHERE trial. CIDP is a rare immune nerve illness. It is often misdiagnosed. A panel of independent experts read medical records. Entry needed 2 judges to agree on definite or probable CIDP. A third judge broke ties.

What they found

560 cases were reviewed. 391 had definite or probable CIDP. 169 did not meet the diagnostic rules for ADHERE. Of 340 enrolled people with phase 1 data, 277 had both judges agree. 50 people with definite or probable CIDP failed other rules. Most clashes came from different views of clinical and nerve test rules.

What it means for patients

The team says the panel tackled the problem of misdiagnosis. They say it made it likelier that the trial included people with confirmed CIDP.

Why it is not certain yet

This describes how one trial checked its people. It is not a treatment result. Experts disagreed in some cases. The abstract gives no treatment results. Some of the work is not described there. Full data tables are not shown.

Source

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

We restate facts from the source record in our own words. The original wording belongs to its publisher.